Gordian Holdings, Inc.

Gordian utilizes the functioning and reactivating the immune system of the human body to destroy cancerous tumors, with our Marvax™ therapy. Unlike current standard of care which sometimes impedes or destroys the immune system.  
We have developed systems and solutions enabling us to ship our product produced here in Texas and tailor made for each patient utilizing genomics and other proprietary diagnostic tools world wide at 38F next day. We enhance MRI's with Bayesian Math and AI. 
 We then utilize block chain to get paid and institute tracking software 24-7 working with Verizon and Samsung following the patients progress through the Intranet. We utilize COROB AI, block chain, the Intranet, and best of all the patients own immune system in fighting and defeating cancer. 
 We have structured the investment in our technology in a way that has the IRS through 41-C R&D partnership pays for your investment going back three years on passive income taxes paid and allowing you a further 20% refund on future passive income taxes. That includes real estate income even if you own it. Helping us defeat cancer in the process. 
 We are also in the process of raising capital to accomplish a reverse merger and then have 6 spin offs, once Phase I with the US FDA is up and running, in essence an exit strategy from the start.
 We qualify as disruptive in the current "standard of care" treatment of cancer. No hospitalization, cost effective treatment no deliriousness after effects.
 Management has a great track record in returns to investors over the last 40 years, and has built and managed a Fortune 500 private company. As well as a profitable short term exit strategy after you invest. 
 We were shut down by COVID patient enrollment restrictions, while in Phase I and are re-initiating that with the US FDA. We have already had 3 meetings with them and they agreed we could go forward after they reviewed translations from our Chinese Jt. Venture partner which conducted the research. We are in the process of doing that. 
    If that is not acceptable then we will test on nude mice here in Houston. 
 Everything is formulated here in Texas, tailor-made for each patient, and then Marvax™ is sent out from TMC World Wide.
    	Marvax™ Utilizing the Human Body  in  Defeating Cancer and Disease  Through Cost Effective Immunogens. Shrinking cancerous tumors in 11 major cancers. 
 Cost Effective: Marvax™ costs $20,000 with no hospital stay. It takes 20 minutes to treat the patient tailor made for each individual in Texas and shipped World Wide.  We enable the patients’ immune system to fight the cancer in real time at home. We then track the patients progress as the tumors shrink utilizing a mobile sonogram that is FDA approved, also in real time with data HIPPA protected on Verizon's Intranet.
 Our management team has over 40 years of investing and managing public and private companies involved in cancer research and development which has led to approval by the FDA in a number of them.  As CEO our chairman built and managed a private Fortune 500 Company Doane Pet Care. 
         We are enclosing our offering documents for our reverse merger common stock offering of $10 Million We are also raising $25 in cash $5 million in services in our second IRS-41-C limited partnership offering, Marshall PartnersWW, LP. 
We are in negotiations for marketing, distribution, and treatment with: China, Poland, Singapore, Italy, UK, Spain, Japan and South Korea where our Joint venture partners will form a company in their country of which we will own a minority position and they will pay us a marketing fee of $25 Million, purchase Marvax™  from us at $15,000 a dose and we will have a net profits split and control through the joint venture agreement with expenses. Marvax™ will only be made in Houston, Texas and shipped overnight with a RISC chip and UPC code for that patient. 
They only allow 10mb in sending info to you. 
We also have a PPM prepared for the $30 Million IRS-41-C partnership and an excel spread sheet which outlines the returns and values prepared by outside CFA's and investment bankers.



Peter P. Smetek, Jr.
Chairman CEO/CSO
Gordian Holdings, Inc.
281-777-5489
[email protected]